Calliditas Therapeutics AB announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon® delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy.
Calliditas Therapeutics AB announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon® delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy.